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A novel, simple and economic reverse phase high performance liquid chromatography (RP-HPLC) method has
been developed for the quantification of Meloxicam in bulk and tablet dosage form with greater precision
and accuracy. Separation was achieved on Develosil ODS HG-5 RP C18, (15 cm × 4.6 mm i.d. 5 μm) column in
isocratic mode with mobile phase consisting of acetonitrile: phosphate buffer(pH 3.4) (60:40) with a flow rate
of 1 mL/min. The detection was carried out at 268 nm. The retention time of Meloxicam was found to be
2.09 min. The method was validated as per ICH guidelines. Linearity was established for Meloxicam in the range
20 – 120 μg/ml with R2 value 0.996. The percentage recovery of Meloxicam was found to be in the range
99.99-100.46%. The high recovery and low relative standard deviation confirm the suitability of the proposed method
for the estimation of the drug in bulk and tablet dosage forms. Validation studies demonstrated that the
proposed RP-HPLC method is simple, specific, rapid, reliable and reproducible for the determination of Meloxicam
for Quality Control level.
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Meloxicam (MEL), shown in Figure 1, is chemically,
4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H,1,2-
benzothaizine-3-carboxamide-1, 1-dioxide. It is used for
the treatment of osteoarthritis, rheumatoid arthritis,
and pauciarticular and polyarticular course juvenile
rheumatoid arthritis. Its analgesic, antipyretic and anti-
inflammatory activity is due to the inhibition of COX-2
enzyme (Noble & Balfour 1996; Davies & Skjodt 1999).
Meloxicam pharmacological activity is greatly affected
by the substituents on parent oxicam moiety e.g. change
in methyl to ethyl at 2 positions causes complete sup-
pression of activity (Lemke & Williams 2008). Several
analytical methods for the determination of meloxicam
by flourimetry (Hassan 2002), capillary electrophoresis
(Nemutlu & Kir 2003), spectrophotometry (Hassan 2002),
HPLC (Arayne et al. 2005; Farzana & Pradeep 2009;* Correspondence: sahoo.nalini@gmail.com
1Yalamarty Pharmacy College, Tarluwada, Visakhapatnam 530052, AP, India
Full list of author information is available at the end of the article
© 2014 Sahoo et al.; licensee Springer. This is a
Attribution License (http://creativecommons.or
in any medium, provided the original work is pDamle et al. 2009), LC/MS (Wiesner et al. 2003) and
polarographic (Altıokka et al. 2000; Radi et al. 2001a;
Altınöz et al. 2002; Radi et al. 2001b; Rao et al. 2005)
have been reported. The aim of the present work was to
develop and validate a sensitive RP-HPLC method that
can be implemented for the quantification of meloxicam
in bulk as well as in its tablet dosage forms.Experimental
Materials
Pure Meloxicam (MEL) used as working standards, was
purchased from Yarrow chem. Products, Mumbai, India.
Tablets containing 15 mg and 7.5 mg of meloxicam
(MUVERA15 and MOVAC) were obtained from Apollo
Pharmaceuticals Pvt. Ltd, Visakhapatnam, India and
used within their shelf life period. Acetonitrile and water
(HPLC-grade) were purchased from Merck, India. All
other chemicals and reagents employed were of analyt-
ical grade, and purchased from Merck, India.n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Chemical structure of Meloxicam.
Sahoo et al. SpringerPlus 2014, 3:95 Page 2 of 6
http://www.springerplus.com/content/3/1/95Instrumentation
The chromatographic system used comprised of Ana-
lytical technologies ltd UV 2230 UV–vis detector.
Data integration was carried out using A-4000 version
software. Samples were injected into Develosil ODS HG-
5 RP C18 (5 μm, 15 cm × 4.6 mm i.d) column. An Analytical
technologies ltd.sonicator was used for enhancing the
dissolution of the compounds. A Wenster digital pH
meter was used for pH adjustment.Chromatographic conditions
The high performance liquid chromatographic (HPLC)
system used was operated isocratically with the col-
umn temperature maintained at 30°C, using a mobile
phase composition of acetonitrile and phosphate buffer
(pH adjusted to 3.4 with O-Phosphoric acid) in the ra-
tio of 60:40 v/v at a flow rate of 1.0 mL/min within a
run time of 7 min. Prior to use, the mobile phase was
degassed by an ultrasonic bath and filtered by a Milli-
pore vacuum filter system equipped with a 0.45 μm
high vacuum filter. The drug was detected and quanti-
fied at 268 nm.Table 1 Results of optimization
Column used Mobile phase Flow rat
Microbondapak C18, 5 μm,
50 × 4.6 mm i.d.
Methanol only 0.5 ml/m
Phenomenex RP- C18, Luna 5 μm,
250 × 4.6 mm i.d.
Acetonitrile only 0.8 ml/m
Microbondapak C18, 5 μm,




Phenomenex RP- C18, Luna 5 μm,
250 × 4.6 mm i.d.
Acetronitrile: phosphate
buffer(pH 5.0 = 60:40
1 ml/min
Develosil ODS HG-5 RP C18, 5 μm,
15cm × 4.6 mm i.d.
Acetonitrile: phosphate
buffer(pH 3.4) (60:40)
1 ml/minPreparation of standard solutions
The stock solution was prepared by transferring 100 mg
of Meloxicam into 100 mL volumetric flask. Then it was
added with small amount of diluent [acetonitrile: water
(50:50)], and the mixture was sonicated to dissolve and
made up to volume with mobile phase. From this stock
solution different concentrations were prepared to give
final concentrations of 20 – 120 μg/mL for standard
calibration curve.Assay of meloxicam from marketed tablets
Twenty tablets were accurately weighed and crushed to
a fine powder in a mortar in each of the marketed for-
mulation separately. An amount of the powder equiva-
lent to 100 mg was transferred into a 100 mL volumetric
flask and 10 mL of diluent was added to it followed by
10 ml of 0.1 N NaOH. The mixture was sonicated to dis-
solve the exipients and then made up to volume with
mobile phase. Following 15 min of mechanical shaking,
it was kept in an ultrasonic bath for 15 mins, and the so-
lution was filtered through a 0.45 μm filter paper. Suit-
able aliquots (1 ml each) of the filtered solution weree Wave length Observation Result
in 254 nm Low resolution below 1. Method rejected
in 358 nm Resolution i.e. 1.2 but
not satisfied
Method rejected
270 nm Poor resolution i.e. 1.5 Method rejected
270 nm Poor resolution i.e. 1.2 Method rejected
268 nm Sharp peak and good
resolution i.e. 2.3
Method accepted
Table 2 Results of linearity and range







Figure 2 RP-HPLC Chromatogram of Meloxicam standard drug.
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volume with mobile phase to yield six concentrations of
Meloxicam (20 μg/mL). A 20 μL volume of the sample
solution was injected into the chromatographic system,
six times, under optimized chromatographic conditions.
The peak areas were measured at 268 nm and concen-
trations in the samples were determined by interpolation
from standard calibration curve of each drug previously
obtained.Method validation
The method was validated in accordance with ICH guide-
lines (International Conference on Harmonization (ICH)
of Technical Requirements for Registration of Pharmaceu-












Figure 3 Calibration curve for Meloxicam.linearity, accuracy, and limit of detection (LOD), limit of
quantification (LOQ), precision, reproducibility, robustness
and system suitability.
Accuracy
Accuracy was best determined by the standard addition
method. Previously analyzed samples of Meloxicam API
were added with standard drug solutions and are analyzed
by the proposed method. Recovery (%), RSD (%) and
bias (%) were calculated for each concentration.
Accuracy is reported as percentage bias, which is cal-
culated from the expression




Precision was determined as both repeatability and inter-
mediate precision, in accordance with ICH guidelines.
Repeatability of sample injection was determined as
intraday variation and intermediate variation. For these
determinations, single concentration (20 μg/ml) at dif-
ferent time intervals and different days, of the solution





Table 5 Results of robustness test
Change in parameter % RSD (n = 6)
Flow (0.9 ml/min) 0.14
Flow (1.1 ml/min) 0.02
Wavelength of Detection (270 nm) 0.09
Wavelength of detection (266 nm) 0.61
Acetonitrile: Phosphate buffer (62:38) 0.14
Acetonitrile: Phosphate buffer (58:42) 0.19





Mean amount (μg )
found (n = 6)
Mean %
recovery
% RSD % Bias
32 32.148 100.46 1.662 0.462
40 40.021 100.05 1.502 0.052
48 47.954 99.99 0.2757 −0.095
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The concept of robustness of an analytical procedure
has been defined by the ICH as “a measure of its capacity
to remain unaffected by small but deliberate variations in
method parameters”. To determine the robustness of the
method experimental conditions are purposely altered
and chromatographic characters are evaluated. Influence
of small changes in chromatographic conditions such as
change in flow rate (± 0.1 ml/min), wavelength of detec-
tion (±2 nm) and acetonitrile content in mobile phase
(±2%) were studied to determine the robustness of the
method.Limit of detection (LOD)
The limit of detection (LOD) of an analytical method
may be defined as the concentration, which gives rise
to an instrument signal that is significantly different
from the blank. For spectroscopic techniques or other
methods that rely upon a calibration curve for quantita-
tive measurements, the IUPAC approach employs the
standard deviation of the intercept (Sa), which may be
related to LOD and the slope of the calibration curve,
b, by
LOD ¼ 3 Sa=b
Limit of quantitation (LOQ)
The LOQ is the concentration that can be quantitated
reliably with a specified level of accuracy and precision.
The LOQ represent the concentration of analyte that





Mean (n = 6) % RSD
9 A.M 22.463 0.01
1 P.M 22.463 0.01
5 P.M 22.463 0.01LOQ ¼ 10 Sa=b
Where, Sa is the standard deviation of the peak area
ratio of analyte to IS (6 injections) of the drugs and b is
slope of the corresponding calibration curve.
Results and discussion
Optimization of chromatographic conditions
The chromatographic conditions were optimized by dif-
ferent means i.e. using different column, different mobile
phase, different flow rate, different detection wavelength
and different diluents for standard drug and marketed
tablets are summarized in Table 1 and different chro-
matograms (Figure 2) are shown.
Linearity & range
The standard calibration curve(Figure 3) showed good
linearity in the range of 20 – 120 μg/ml (Table 2), for
Meloxicam API with correlation coefficient (r2) of 0.996.
A typical calibration curve has the regression equation
of y = 37461x + 158481 for Meloxicam.
Accuracy: recovery study
The recovery of the method, determined by adding a
previously analyzed test solution with additional drug
standard solution at three levels of concentration, was
99.99 - 100.46%. The values of recovery (%), RSD (%) and
% Bias listed in Table 3 indicate the method is accurate.
Precision: Intra-assay & inter-assay
The intra & inter day variation of the method was car-
ried out and the high values of mean assay and lowf Meloxicam (μg/ml) by the proposed method
Inter-Day
Mean (n = 6) % RSD
Day 1 21.89 0.08
Day 2 21.93 0.04
Day 3 20.99 0.01
Table 6 Assay of meloxicam tablets
S. No Formulations Standard peak area Sample peak area Labeled amount (mg) Amount found (mg) % Assay ± RSD
1 Muvera 15 1000024 1000011 15 14.99 99.99 ± 0.12
2 Movac 1000024 1000191 7.5 7.5 100.01 ± 0.02
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within a day and day to day variations for Meloxicam re-
vealed that the proposed method is precise (Table 4).Robustness
Influence of small changes in chromatographic condi-
tions such as change in flow rate (± 0.1 ml/min), Wave-
length of detection (±2 nm) & acetonitrile content in
mobile phase (±2%) studied to determine the robustness
of the method are also in favor of (Table 5, % RSD < 2%)
the developed RP-HPLC method for the analysis of
Meloxicam API.LOD & LOQ
The Minimum concentration level at which the analyte
can be reliable detected (LOD) & quantified (LOQ) were
found to be 0.42 & 1.29 μg/ml respectively.Assay of meloxicam in tablet dosage forms
Assay was performed by using the regression equation
(y = 37461x + 158481, R2 = 0.996) obtained from the stand-
ard calibration curve of Meloxicam API. Results obtained
are given in Table 6. The assay of Muvera 15 and Movac
tablet containing Meloxicam was found to be 99.99 and
100.01% respectively as per the method. The chromato-
grams are represented in Figures 4 and 5.Figure 4 RP-HPLC Chromatogram of Muvera 15 Tablet.The method is having linearity in the range 20 to
120 μg/ml with regression coefficient value 0.99. When
compared to previous methods for recovery study, the %
recovery is nearly 100%. Precision results are having low
% RSD value i.e. below 0.1 in comparison to previous
methods, which is an added advantage. Similarly in previ-
ous methods assay in marketed formulation is carried
out by considering single formulation, but the present
method uses two different formulations. Also at very low
concentration it can be detected and quantified i.e. at
0.42 & 1.29 μg/ml, which is not observed in previous
methods. For these reasons the method is proved to be
novel in comparision to existed methods.Conclusion
A New RP-HPLC method indicating assay of MEL in
bulk and in pharmaceutical dosage forms is established.
This method is simple, reliable, linear, accurate, sensitive
and reproducible as well as cost effective for the effective
quantitative analysis of MEL in bulk and tablet formula-
tions. The method was completely validated showing
satisfactory data for all the method validation parameters
tested and method is free from interference of the other
active ingredients and additives used in the formulations.
Therefore the method is suitable for use of the routine
quality control analysis of Meloxicam in API or in pharma-
ceutical dosage forms.Figure 5 RP-HPLC Chromatogram of Movac Tablet.
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